Status Epilepticus in Older Adults: Diagnostic and Treatment Considerations

• Published in: Drugs & aging 2023-02, Vol.40 (2), p.91-103
• Main Authors: Osman, Gamaleldin M., Hocker, Sara E.
• Format: Article
• Language: English
• Subjects: Adults; Age groups; Aged; Alzheimer's disease; Anticonvulsants - therapeutic use; Benzodiazepines; Benzodiazepines - therapeutic use; Brain cancer; Cerebrovascular disease; Consciousness; Convulsions & seizures; Diazepam - therapeutic use; Epilepsy; Etiology; Geriatrics/Gerontology; Humans; Infections; Internal Medicine; Ketamine; Leading Article; Medical diagnosis; Medicine; Medicine & Public Health; Metabolism; Midazolam - therapeutic use; Morbidity; Mortality; Older people; Pharmacology/Toxicology; Pharmacotherapy; Pneumonia; Status Epilepticus - diagnosis; Status Epilepticus - drug therapy; Systematic review
• ISSN: 1170-229X; 1179-1969
• DOI: 10.1007/s40266-022-00998-z

Status epilepticus (SE) is one of the leading life-threatening neurological emergencies in the elderly population, with significant morbidity and mortality. SE presents unique diagnostic and therapeutic challenges in the older population given overlap with other causes of encephalopathy, complicating diagnosis, and the common occurrence of multiple comorbid diseases complicates treatment. First-line therapy involves the use of rescue benzodiazepine in the form of intravenous lorazepam or diazepam, intramuscular or intranasal midazolam and rectal diazepam. Second-line therapies include parenteral levetiracetam, fosphenytoin, valproate and lacosamide, and underlying comorbidities guide the choice of appropriate medication, while third-line therapies may be influenced by the patient’s code status as well as the cause and type of SE. The standard of care for convulsive SE is treatment with an intravenous anesthetic, including midazolam, propofol, ketamine and pentobarbital. There is currently limited evidence guiding appropriate therapy in patients failing third-line therapies. Adjunctive strategies may include immunomodulatory treatments, non-pharmacological strategies such as ketogenic diet, neuromodulation therapies and surgery in select cases. Surrogate decision makers should be updated early and often in refractory episodes of SE and informed of the high morbidity and mortality associated with the disease as well as the high probability of subsequent epilepsy among survivors.